The spevigo market research report is one of a series of new reports that provides spevigo market statistics, including the spevigo industry's global market size, regional shares, competitors with a spevigo market share, detailed spevigo market segments, market trends and opportunities, and any further data you may need to thrive in the spevigo industry. This spevigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing awareness and diagnosis of generalized pustular psoriasis (GPP), expanding regulatory approvals in emerging markets, growing investment in dermatology R&D, rising healthcare expenditure, improved access to specialty medications, and rising focus on patient-centric treatment approaches. Major trends in the forecast period include advancements in biologic therapies, advancements in drug delivery systems, adoption of biologic treatments, and innovation in formulations.
The increasing prevalence of generalized pustular psoriasis (GPP) is expected to drive the growth of the Spevigo market in the future. GPP is a rare and severe form of psoriasis marked by widespread pustules and inflammation on the skin. The rise in GPP cases is partly due to improvements in diagnostic techniques, greater awareness among healthcare providers, and potential genetic or environmental factors. Spevigo treats GPP by targeting and blocking the interleukin-36 receptor, which is a crucial pathway involved in the immune response in GPP. By inhibiting this receptor, Spevigo reduces inflammation and clears pustules, leading to significant symptom improvement. According to a report published by Oxford Academic in May 2023, the prevalence of GPP is about 198 cases per million, with women being more affected (267 per million) than men (127 per million). The incidence rate of GPP is 27.2 new cases per million person-years, with women at 35.3 and men at 18.3 per million person-years. The rising prevalence of GPP is expected to continue driving growth in the Spevigo market.
The increase in healthcare spending is also expected to propel the growth of the Spevigo market. Healthcare spending encompasses the total financial resources allocated to medical treatments, medications, and hospital care over a specific period. This spending is growing due to factors such as an aging population, increasing healthcare demands, medical technology advancements, and rising service and medication costs. Higher healthcare spending facilitates access to innovative treatments such as Spevigo by improving diagnostic capabilities, expanding treatment infrastructure, and making therapies more affordable through reimbursement policies. A report from the Office for National Statistics in May 2024 revealed that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to just 0.9% growth in 2022. This growing healthcare expenditure is expected to fuel the expansion of the Spevigo market.
A key trend in the Spevigo market is the ongoing focus on expanding its reach and enhancing geographic coverage, which will help increase patient access and strengthen its competitive position. This expansion is supported by strategic partnerships, regulatory approvals, and targeted marketing efforts aimed at increasing availability in different regions. For example, in May 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval for Spevigo from the Central Drugs Standard Control Organization (CDSCO) in India. Spevigo (spesolimab) is the first treatment for GPP flares in adults. In clinical trials, such as the EFFISAYIL 1 Phase II trial, 54% of patients treated with Spevigo achieved pustule clearance within a week, compared to just 6% in the placebo group. This demonstrated the drug's efficacy, further promoting its market expansion.
The key company operating in the spevigo market is C.H. Boehringer Sohn AG & Co. KG.
North America was the largest region in the spevigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spevigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the spevigo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Spevigo (spesolimab) is a monoclonal antibody used to treat generalized pustular psoriasis (GPP), a rare and severe form of psoriasis. It works by targeting and inhibiting the interleukin-36 receptor, which is crucial in the inflammatory process of GPP. Spevigo is designed to reduce symptoms and flare-ups associated with this condition, providing an effective treatment option for patients with moderate to severe GPP.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indication for Spevigo is generalized pustular psoriasis (GPP), with potential use in other neutrophilic skin diseases currently under investigation. GPP is a rare and severe form of psoriasis marked by widespread pustules (blisters filled with pus) on the skin, along with fever, chills, and other systemic symptoms. If not treated promptly, it can be life-threatening. The treatment aims to control flare-ups and manage symptoms to enhance the patient's quality of life. Spevigo is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used across various age groups, including pediatric, adult, and geriatric populations.
The spevigo market consists of sales of spevigo (spesolimab) injections and solutions. Values in this market are ‘factory gate’ values, representing the goods sold directly by manufacturers to downstream entities or end customers. This includes sales of therapies, related services, and distribution costs.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing awareness and diagnosis of generalized pustular psoriasis (GPP), expanding regulatory approvals in emerging markets, growing investment in dermatology R&D, rising healthcare expenditure, improved access to specialty medications, and rising focus on patient-centric treatment approaches. Major trends in the forecast period include advancements in biologic therapies, advancements in drug delivery systems, adoption of biologic treatments, and innovation in formulations.
The increasing prevalence of generalized pustular psoriasis (GPP) is expected to drive the growth of the Spevigo market in the future. GPP is a rare and severe form of psoriasis marked by widespread pustules and inflammation on the skin. The rise in GPP cases is partly due to improvements in diagnostic techniques, greater awareness among healthcare providers, and potential genetic or environmental factors. Spevigo treats GPP by targeting and blocking the interleukin-36 receptor, which is a crucial pathway involved in the immune response in GPP. By inhibiting this receptor, Spevigo reduces inflammation and clears pustules, leading to significant symptom improvement. According to a report published by Oxford Academic in May 2023, the prevalence of GPP is about 198 cases per million, with women being more affected (267 per million) than men (127 per million). The incidence rate of GPP is 27.2 new cases per million person-years, with women at 35.3 and men at 18.3 per million person-years. The rising prevalence of GPP is expected to continue driving growth in the Spevigo market.
The increase in healthcare spending is also expected to propel the growth of the Spevigo market. Healthcare spending encompasses the total financial resources allocated to medical treatments, medications, and hospital care over a specific period. This spending is growing due to factors such as an aging population, increasing healthcare demands, medical technology advancements, and rising service and medication costs. Higher healthcare spending facilitates access to innovative treatments such as Spevigo by improving diagnostic capabilities, expanding treatment infrastructure, and making therapies more affordable through reimbursement policies. A report from the Office for National Statistics in May 2024 revealed that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to just 0.9% growth in 2022. This growing healthcare expenditure is expected to fuel the expansion of the Spevigo market.
A key trend in the Spevigo market is the ongoing focus on expanding its reach and enhancing geographic coverage, which will help increase patient access and strengthen its competitive position. This expansion is supported by strategic partnerships, regulatory approvals, and targeted marketing efforts aimed at increasing availability in different regions. For example, in May 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval for Spevigo from the Central Drugs Standard Control Organization (CDSCO) in India. Spevigo (spesolimab) is the first treatment for GPP flares in adults. In clinical trials, such as the EFFISAYIL 1 Phase II trial, 54% of patients treated with Spevigo achieved pustule clearance within a week, compared to just 6% in the placebo group. This demonstrated the drug's efficacy, further promoting its market expansion.
The key company operating in the spevigo market is C.H. Boehringer Sohn AG & Co. KG.
North America was the largest region in the spevigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spevigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the spevigo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Spevigo (spesolimab) is a monoclonal antibody used to treat generalized pustular psoriasis (GPP), a rare and severe form of psoriasis. It works by targeting and inhibiting the interleukin-36 receptor, which is crucial in the inflammatory process of GPP. Spevigo is designed to reduce symptoms and flare-ups associated with this condition, providing an effective treatment option for patients with moderate to severe GPP.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indication for Spevigo is generalized pustular psoriasis (GPP), with potential use in other neutrophilic skin diseases currently under investigation. GPP is a rare and severe form of psoriasis marked by widespread pustules (blisters filled with pus) on the skin, along with fever, chills, and other systemic symptoms. If not treated promptly, it can be life-threatening. The treatment aims to control flare-ups and manage symptoms to enhance the patient's quality of life. Spevigo is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used across various age groups, including pediatric, adult, and geriatric populations.
The spevigo market consists of sales of spevigo (spesolimab) injections and solutions. Values in this market are ‘factory gate’ values, representing the goods sold directly by manufacturers to downstream entities or end customers. This includes sales of therapies, related services, and distribution costs.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Spevigo Market Characteristics4. Spevigo Market Trends And Strategies5. Spevigo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Spevigo Pricing Analysis & Forecasts30. Global Spevigo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Spevigo Market32. Recent Developments In The Spevigo Market
3. Spevigo Market Biologic Drug Characteristics
6. Global Spevigo Growth Analysis And Strategic Analysis Framework
8. Spevigo Market Segmentation
9. Global Spevigo Epidemiology Of Clinical Indications
10. Spevigo Market Regional And Country Analysis
11. Asia-Pacific Spevigo Market
12. China Spevigo Market
13. India Spevigo Market
14. Japan Spevigo Market
15. Australia Spevigo Market
16. South Korea Spevigo Market
17. Western Europe Spevigo Market
18. UK Spevigo Market
19. Germany Spevigo Market
20. France Spevigo Market
21. Eastern Europe Spevigo Market
22. North America Spevigo Market
23. USA Spevigo Market
24. Canada Spevigo Market
25. South America Spevigo Market
26. Middle East Spevigo Market
27. Africa Spevigo Market
28. Spevigo Market Competitive Landscape And Company Profiles
29. Global Spevigo Market Pipeline Analysis
33. Spevigo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Spevigo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on spevigo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for spevigo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spevigo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Generalized Pustular Psoriasis (GPP); Potentially Other Neutrophilic Skin Diseases Under Investigation2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Age Group: Pediatric; Adult; Geriatric
Key Companies Profiled: C.H. Boehringer Sohn AG & Co. KG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- C.H. Boehringer Sohn AG & Co. KG
